Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer
Phase of Trial: Phase II
Latest Information Update: 25 May 2015
At a glance
- Drugs Erlotinib (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- 20 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 15 Jan 2013 Planned End Date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 15 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.